Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?
Lymphomas (J Armitage and P McLaughlin, Section Editors)
First Online: 06 June 2012 DOI:
Cite this article as: Goyal, S.D. & Bartlett, N.L. Curr Hematol Malig Rep (2012) 7: 179. doi:10.1007/s11899-012-0126-1 Abstract
Brentuximab vedotin is an antibody-drug conjugate that targets CD30 and links monomethyl auristatin E, a microtubule disrupting agent, to an anti-CD30 monoclonal antibody. A phase II study of brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma (cHL) showed an impressive overall response rate of 75 % with 34 % complete responses, and median remission duration of 20 months in complete responders. In addition, brentuximab vedotin has very modest toxicity in heavily pretreated patients, with reversible peripheral neuropathy being the most common side effect. Brentuximab vedotin received accelerated FDA approval in August 2011 for use as a salvage therapy in cHL following failure of at least two prior therapies. Brentuximab vedotin is the treatment of choice for patients relapsing after stem cell transplant and for patients refractory to standard salvage regimens pre-transplant. Because of high single-agent activity and limited side effects, brentuximab vedotin has emerged as an ideal drug to test in combination therapy for cHL. Current trials are examining the use of brentuximab vedotin in frontline combination regimens, as salvage therapy prior to stem cell transplant, and as adjuvant treatment post-transplant. Such studies will help clarify the optimal use of brentuximab vedotin in the treatment paradigm for Hodgkin lymphoma.
Keywords Brentuximab vedotin Classical Hodgkin lymphoma CD30 Antibody drug conjugate Neuropathy stem cell transplantation References Papers of particular interest, published recently, have been highlighted as: • Of importance
Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12:1065–72.
Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. ASH Educ Program Book. 2008;2008:326–33.
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21.
This phase I study demonstrated safety and efficacy of the every 3 week dosing schedule for brentuximab vedotin
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012 epub.
This phase II study demonstrated a high response rate for brentuximab vedotin in patients with heavily pretreated Hodgkin lymphoma. It showed highly durable remissions in the group of patients that achieved a complete response to therapy. The results from this study led to accelerated approval for brentuximab vedotin as salvage therapy for Hodgkin lymphoma.
Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111:1848–54.
Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171–9.
Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol. 2010;21:2246–54.
Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A Phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18:248–55.
Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin’s disease following autologous bone marrow transplant. J Clin Oncol. 1998;16:584–8.
Rule S, Tighe M, Davies S, Johnson S. Vinorelbine in the treatment of lymphoma. Hematol Oncol. 1998;16:101–5.
Venkatesh H, Di Bella N, Flynn TP, et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clin Lymphoma. 2004;5:110–5.
Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica. 2000;85:926–9.
Bartlett N, Grove L, Kennedy A, et al. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series, ASCO Annual Meeting Abstracts. 2010;28(15s):8062.
Foyil KV, Kennedy DA, Grove LE, et al. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. Leuk Lymphoma. 2011;53(3):506–7.
Forero-Torres A, Berryman RB, Advani RH, et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL), ASH Annual Meeting Abstracts. 2011;118:3711
Chen R, Forman SJ, Palmer J, et al. Brentuximab vedotin (SGN-35) enables successful reduced intensity allogeneic hematopoietic cell transplantation in relapsed/refractory Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2011;118:664.
Illidge T, Bouabdallah R, Chen RW, et al. Allogeneic transplant following brentuximab vedotin treatment in patients with relapsed or refractory CD30+ lymphomas. ASH Annual Meeting Abstracts. 2011;118:3091.
Younes A, Connors JM, Park SI, et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma, ASH Annual Meeting Abstracts. 2011;118:955.
Wagner-Johnston ND, Bartlett NL, et al. Progressive multifocal leukoencephalopathy (PML) in a patient with Hodgkin’s lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012; Mar 16 epub.
© Springer Science+Business Media, LLC 2012